Can-Fite BioPharma (CANF) Competitors $0.62 +0.01 (+1.50%) Closing price 10/3/2025 03:57 PM EasternExtended Trading$0.61 0.00 (-0.65%) As of 10/3/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CANF vs. QLGN, TNFA, CELZ, APRE, RNAZ, VYNE, VIVS, CSCI, BCDA, and PALIShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Qualigen Therapeutics (QLGN), TNF Pharmaceuticals (TNFA), Creative Medical Technology (CELZ), Aprea Therapeutics (APRE), TransCode Therapeutics (RNAZ), VYNE Therapeutics (VYNE), VivoSim Labs (VIVS), COSCIENS Biopharma (CSCI), BioCardia (BCDA), and Palisade Bio (PALI). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Its Competitors Qualigen Therapeutics TNF Pharmaceuticals Creative Medical Technology Aprea Therapeutics TransCode Therapeutics VYNE Therapeutics VivoSim Labs COSCIENS Biopharma BioCardia Palisade Bio Can-Fite BioPharma (NYSE:CANF) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends. Does the media favor CANF or QLGN? In the previous week, Qualigen Therapeutics had 5 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 6 mentions for Qualigen Therapeutics and 1 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 1.00 beat Qualigen Therapeutics' score of 0.51 indicating that Can-Fite BioPharma is being referred to more favorably in the media. Company Overall Sentiment Can-Fite BioPharma Positive Qualigen Therapeutics Positive Is CANF or QLGN more profitable? Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A Qualigen Therapeutics N/A N/A -202.16% Do institutionals and insiders hold more shares of CANF or QLGN? 21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend CANF or QLGN? Can-Fite BioPharma currently has a consensus price target of $14.50, suggesting a potential upside of 2,257.72%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Can-Fite BioPharma is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has stronger earnings and valuation, CANF or QLGN? Qualigen Therapeutics has higher revenue and earnings than Can-Fite BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$560K3.89-$7.63M-$1.79-0.34Qualigen Therapeutics$4.98M1.79-$6.26MN/AN/A Which has more volatility and risk, CANF or QLGN? Can-Fite BioPharma has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. SummaryCan-Fite BioPharma beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.18M$805.16M$6.12B$21.82BDividend YieldN/A4.84%5.66%3.54%P/E Ratio-0.341.2586.8829.82Price / Sales3.89123.93587.4067.71Price / CashN/A17.6426.3018.31Price / Book0.356.9612.534.65Net Income-$7.63M-$7.70M$3.30B$1.00B7 Day PerformanceN/A1.30%3.53%1.20%1 Month Performance-5.53%4.72%6.77%3.32%1 Year Performance-68.78%45.15%70.60%13.11% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma3.2547 of 5 stars$0.62+1.5%$14.50+2,257.7%-68.8%$2.18M$560K-0.348Positive NewsShort Interest ↓Gap UpQLGNQualigen TherapeuticsN/A$5.38+6.3%N/A-36.8%$8.58M$4.98M0.0050TNFATNF Pharmaceuticals0.1491 of 5 stars$4.64-1.3%N/A-96.3%$8.57MN/A-0.026Negative NewsShort Interest ↑Gap UpCELZCreative Medical Technology0.819 of 5 stars$3.31flatN/A+7.7%$8.53M$10K-1.045Positive NewsAPREAprea Therapeutics2.2189 of 5 stars$1.51+3.4%$15.50+926.5%-42.3%$8.50M$1.50M-0.657Positive NewsRNAZTransCode Therapeutics1.5045 of 5 stars$10.63+4.5%$280.00+2,535.0%-99.9%$8.48MN/A0.009Positive NewsVYNEVYNE Therapeutics2.6135 of 5 stars$0.33-0.8%$6.25+1,799.7%-80.3%$8.45M$500K-0.3730VIVSVivoSim Labs0.2454 of 5 stars$3.02-5.9%N/AN/A$8.35M$140K-0.3020Positive NewsCSCICOSCIENS BiopharmaN/A$2.61-15.3%N/A-29.5%$8.29M$9.44M-0.4320Gap DownHigh Trading VolumeBCDABioCardia3.7962 of 5 stars$1.40-1.4%$25.00+1,685.7%-50.4%$8.25M$60K-0.7640Positive NewsShort Interest ↓PALIPalisade Bio2.2828 of 5 stars$0.92+2.6%$12.00+1,201.9%-53.4%$8.19M$250K-0.2310News CoverageShort Interest ↑Gap Up Related Companies and Tools Related Companies Qualigen Therapeutics Alternatives TNF Pharmaceuticals Alternatives Creative Medical Technology Alternatives Aprea Therapeutics Alternatives TransCode Therapeutics Alternatives VYNE Therapeutics Alternatives VivoSim Labs Alternatives COSCIENS Biopharma Alternatives BioCardia Alternatives Palisade Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
